Aspirin Decreases Hepatocellular Carcinoma Risk in Hepatitis C Virus Carriers: A Nationwide Cohort Study

Yen-Hsiang Liao
Hualien Tzu Chi Hospital

Ren-Jun Hsu
Hualien Tzu Chi Hospital

Tzu-Hwei Wang
Hualien Tzu Chi Hospital

Chen-Ta Wu
Hualien Tzu Chi Hospital

Sheng-Yao Huang
Hualien Tzu Chi Hospital

Chung-Y. Hsu
Hualien Tzu Chi Hospital

Yuan-Chih Su
Hualien Tzu Chi Hospital

Wen-Lin Hsu
Hualien Tzu Chi Hospital

Dai-Wei Liu (✉ wuchentatzuchi@gmail.com)

Research article

Keywords: Aspirin, Hepatitis C virus carrier, Hepatocellular Carcinoma

Posted Date: December 10th, 2019

DOI: https://doi.org/10.21203/rs.2.14963/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published on January 9th, 2020. See the published version at https://doi.org/10.1186/s12876-020-1158-y.
Abstract

Background

Aspirin has been found to lower the occurrence rates of some cancers through the inhibition of the cyclooxygenase enzyme. For example, there is a well-known association between aspirin use and the occurrence of hepatocellular carcinoma (HCC) in hepatitis B virus (HBV) carriers. However, the association, if any, between aspirin use and HCC in hepatitis C virus (HCV) carriers is unknown. Therefore, this study compared the occurrence rates of HCC in HCV carriers treated with or without aspirin.

Methods

The participants in this retrospective cohort study consisted of people newly diagnosed with HCV in Taiwan from 2000 to 2012. Those who were treated with aspirin were defined as the control group, whereas those not treated with aspirin were defined as the comparison cohort. We used a 1:1 propensity score matching by age, sex, comorbidities, drugs, diagnosis year, and index year with covariate assessment.

Results

Our study sample consisted of 2980 aspirin-treated HCV carriers and 7771 non-aspirin-treated HCV carriers. After propensity score matching, each cohort consisted of 1911 HCV carriers. The adjusted hazard ratio (aHR) of HCC incidence in the aspirin users (aHR=0.56, 95% CI=0.43-0.72, p < 0.001 ) was significantly lower than that in the non-aspirin users. A Kaplan-Meier analysis showed that among the HCV carriers, the aspirin users had a lower cumulative incidence rate of HCC over the first 10 years of aspirin treatment ( p < 0.0001 ).

Conclusions

The HCC incidence rate was lower in the aspirin-using HCV carriers than in the non-aspirin-using HCV carriers, indicating that the effects of aspirin might occur through inhibition of the cyclooxygenase enzyme pathway. Moreover, protection from HCC was provided by less than a year of aspirin treatment, while treatment with aspirin for 1 to 2 years exhibited the greatest protective effect. We therefore encourage aspirin treatment to prevent HCC in HCV carriers.

Background

Hepatocellular carcinoma (HCC) is one of the most common malignant neoplasms in the world. The incidence of HCC has increased not only in the United States [1] but also in Taiwan [2]. Hepatitis B virus (HBV) infections, hepatitis C virus (HCV) infections, and alcoholic liver cirrhosis are the main risk factors for HCC [3–5]. Chronic inflammation occurring through the COX-2 pathway is one of the most important process in the induction not only of liver cirrhosis but also of HCC [6].
Aspirin has been widely used as an analgesic and anti-inflammatory drug. It also plays an important role in preventing cerebrovascular and cardiovascular thrombosis and even lowering the associated mortality, especially in diabetes mellitus patients [7–10]. Aspirin may also prevent the occurrence of some cancers, such as colorectal cancer [11–14], lung cancer [15], prostate cancer [16], and head and neck cancer [17], as well as HCC [18]. Its effects are likely due to the inhibition of the cyclooxygenase enzyme. Aspirin, therefore, prevents carcinogenesis, cell invasion, angiogenesis, and metastasis through its promotion of prostanoid synthesis [19]. It also induces apoptosis by altering the Bax/Bcl–2 ratio and activating death receptors [19].

After being infected with HCV, a patient becomes an HCV carrier. Aspirin treatment can decrease the occurrence of HCC through the inhibition of the cyclooxygenase enzyme pathway. Some retrospective reports have shown that aspirin decreases the incidence of HCC [18, 20]. However, the association between aspirin use and the incidence of HCC has been evaluated only in HBV carriers, not in HCV carriers [21].

Therefore, we conducted a nationwide cohort study to evaluate the association between aspirin use and the incidence rate of HCC in HCV carriers.

**Methods**

**Data sources**

We used the Longitudinal Health Insurance database 2000 (LHID2000) to conduct this cohort study. The LHID2000 is a sub-dataset of Taiwan’s National Health Insurance Research Database (NHIRD) that contains 1 million random subjects. The NHIRD contains the medical care data from the National Health Insurance (NHI) program, which covers over 99% of the population of Taiwan. The NHIRD provides diagnosis data according to the International Classification of Diseases, 9th revision, Clinical Modification (ICD–9-CM), as well drug treatment and demographic information, with the identification of each individual included in the database being replaced by a random sequence. The Research Ethics Committee of China Medical University and Hospital in Taichung, Taiwan approved this study (CMUH104-REC2–115(CR–2)).

**Study population**

The study population consisted of subjects who had been newly diagnosed with HCV (ICD–9-CM codes: 070.41, 070.44, 070.51, 070.54, and V02.62) from 2000 to 2012 and had at least two HCV outpatient records or one HCV inpatient record in the database. We then classified the study population of individuals diagnosed with HCV into aspirin users or non-aspirin users. The date on which aspirin was first received was defined as the index date. The exclusion criteria were as follows: (1) age less than 20 years, (2) HBV patient, (3) HIV infection, (4) treatment with an interferon or direct-acting anti-viral before
the index date, and (5) a diagnosis of HCC before the index date. The aspirin users and non-aspirin users were matched using propensity score matching with gender, age, HCV diagnosis year, number of years of aspirin use, and interval between HCV diagnosis and aspirin use.

Main outcome and confounding factors

The main outcome of this study was a new diagnosis of HCC (ICD–9-CM code: 155). Each case of HCC was identified according to the records of the registry for catastrophic illness patients. If another disease occurred before the index date, it was considered as baseline comorbidity. *These comorbidities included hypertension (ICD–9-CM codes: 401–405), diabetes mellitus (ICD–9-CM code: 250), moderate or severe liver disease (ICD–9-CM codes: 456.0–456.2, 572.2–572.4, 572.8), myocardial infarction (ICD–9-CM codes: 410, 412), congestive heart failure (ICD–9-CM codes: 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.13, 404.91, 404.93, 425.4, 425.5, 425.7–425.9, 428), and ischemic stroke (ICD–9-CM codes: 433–436).* The use of medications such as anti-hypertensive agents, hypoglycemic agents, coumadin and heparin, other antithrombotic agents, and non-steroidal anti-inflammatory drugs (NSAIDs) within 180 days before the index date was considered a confounding factor.

Statistical analysis

We analyzed the HCC risk among the HCV carriers treated with aspirin and the HCV carriers not treated with aspirin. The follow-up period was the duration between the index date and the date of occurrence of the main outcome, withdrawal from the NHI program, death or the end of 2013, whichever came first. The crude, adjusted hazard ratios (aHRs) and corresponding 95% confidence intervals (95% CIs) were estimated using a Cox proportional hazards regression model without and with adjustment for gender, age, and confounding factors. We also assessed the aspirin effect among different strata of patient characteristics. We calculated the cumulative incidence of HCC using the Kaplan-Meier method and examined the difference in two trends using the log-rank test. All analyses were performed with the SAS statistical package, version 9.4 (SAS Institute, Cary NC). The significance level was set at 2-tail $p < 0.05$.

Results

We documented 2980 aspirin users and 7771 non-aspirin users among the 16466 individuals newly diagnosed as HCV carriers from 2000 to 2012 (Figure 1). After applying the exclusion criteria to those patients, propensity score matching was applied to 2004 aspirin users and 4606 non-aspirin users. The final study population consisted of 1911 HCV carriers treated with aspirin and 1911 HCV carriers not treated with aspirin. Table 1 shows that there were no significant differences between these aspirin-treated and non-aspirin-treated groups in terms of their gender, age, and baseline comorbidities. However, the proportions of patients in the aspirin-treated group who used antihypertensive agents, coumadin and heparin, antithrombotic agents, and NSAIDs were significantly greater than the proportions of patients in
the non-aspirin-treated group who did so, although there was no significant difference between the two groups in terms of the proportions who used hypoglycemic agents.

Compared with the non-aspirin users, the aspirin users had a lower risk of HCC (adjusted HR = 0.56, 95% CI = 0.43–0.72, \( p < .001 \); Table 2). The lower HCC risk in the aspirin users was further displayed by the cumulative HCC incidence trend (Figure 2). Furthermore, Table 2 demonstrates a 1.71-fold higher HCC risk in the male patients than in the female patients (adjusted HR = 1.71, 95% CI = 1.35–2.18, \( p < .001 \)). The HCC risk was also higher in those individuals who were older than 40 years than in those who were less than 40 years old. The comorbidities were not associated with the risk of HCC in the HCV carriers (that is, the risk of HCC in those individuals with a comorbidity was similar to that in those with no comorbidities). However, the adjusted HR in those who received anti-hypertensive agents was 1.94-fold higher than the adjusted HR in those who did not (95% CI = 1.45–2.6, \( p < .001 \); Table 2). Other medications were not associated with the risk of HCC.

Table 3 shows that aspirin use significantly decreased the risk of HCC in both genders (female: adjusted HR = 0.51, 95% CI = 0.35–0.76, \( p < .001 \); male: adjusted HR = 0.59, 95% CI = 0.42–0.83, \( p < .01 \)). However, with respect to patients in the same age strata, only the aspirin users who were 60 to 79 years old showed a significant decrease in HCC risk compared to the non-aspirin users (adjusted HR = 0.56, 95% CI = 0.41–0.76, \( p < .001 \)). Among the anti-hypertensive agent users, meanwhile aspirin also had an apparent benefit of decreased HCC risk (adjusted HR = 0.53, 95% CI = 0.4–0.71, \( p < .001 \)).

For the aspirin users, we classified the duration of aspirin use into four levels (<1 year, 1–2 years, 2–3 years, \( \geq 3 \) years) while also classifying the non-users according to the same four levels for reference. Among the aspirin users, the most events occurred among those whose duration of aspirin use was less than 1 year (Table 4). Compared with the non-use of aspirin, all of the different durations of aspirin use had significant effects in terms of reducing HCC risk, except the duration of 2–3 years (adjusted HR = 0.6, 95% CI = 0.32–1.13, \( p = 0.11 \)). The lowest adjusted HR was 0.33 (95% CI = 0.18–0.61, \( p < .001 \)), which was found for the aspirin users with a duration of aspirin use of 1–2 years.

**Discussion**

Using a nationwide population database, we investigated the association between the use of aspirin and HCC risk in HCV carriers. This is the first study to find that HCV carriers who used aspirin had a lower risk of HCC than HCV carriers who did not use aspirin (adjusted HR = 0.56, 95% CI = 0.43–0.72, \( p < .001 \); Table 2). Furthermore, the male HCV carriers had a 1.71-fold higher risk of HCC than the female HCV carriers (adjusted HR = 1.71, 95% CI = 1.35–2.18, \( p < .001 \); Table 2), although aspirin treatment significantly reduced the HCC risk in both genders (female: adjusted HR = 0.51, 95% CI = 0.35–0.76, \( p < .001 \); male: adjusted HR = 0.59, 95% CI = 0.42–0.83, \( p < .01 \); Table 3). The Kaplan-Meier curves showed that the HCV carriers treated with aspirin had a lower cumulative incidence rate of HCC than those not treated with aspirin (\( p < .0001 \); Figure 2). In considering the duration of aspirin use, the lowest adjusted HR for developing HCC was 0.33 (95% CI = 0.18–0.61, \( p < .001 \)), which was found in those aspirin users
with a duration of aspirin use of 1–2 years. Overall, the results of our study demonstrate that aspirin treatment can decrease the occurrence of HCC in HCV carriers.

Taiwan is one of the HBV endemic areas and has a substantial proportion of patients with dual HBV and HCV infection [22]. To prevent interference from HBV infections, we excluded HBV carriers in order to purify our study group. Since interferon or direct-acting anti-viral treatment might totally cure an HCV infection [23], our study also excluded those patients who received interferon or direct-acting anti-viral treatment before the index date. This guaranteed that the investigated patients were HCV carriers while also ensuring that any lowering of the HCC occurrence was due only to the use of aspirin.

The HCC risk in the individuals with the comorbidity of hypertension was similar to that in those without hypertension. As shown in Table 2, the comorbidity of hypertension was not associated with an increased occurrence of HCC in our study population. It is interesting, however, to note that the HCC risk among participants receiving anti-hypertensive agents was 1.94-fold higher than that among those not receiving such agents (95% CI = 1.45–2.6, p < 0.001; Table 2). Although our present findings cannot explain this conflict, Ho et al. [24] found that the use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers was associated with higher HCC occurrence in patient subgroups consisting of patients with no cirrhosis, no DM, and no hyperlipidemia. This issue requires further study in the future.

The real mechanism by which aspirin reduces HCC risk in HCV carriers is not well understood. A previous study, however, revealed different pathways for the viral and non-viral carcinogenesis of HCC. In an HBV transgenic mice model, it was found that platelets facilitate immune-mediated liver damage through the accumulation of HBV-specific cytotoxic T lymphocytes (CTLs) [25]. Sitia et al. [26] further found that aspirin decreased T-cell mediated inflammation, liver fibrosis, and progression to HCC in this HBV transgenic mice model. Whether the HBV-related carcinogenesis of HCC and the effect of aspirin on immunomodulation are the same as in HCV is still under investigation. However, aspirin has been found to have antioxidative and antiviral activity in HCV-expressing cells through Cu/Zn superoxide dismutase (SOD1) induction [27] and the downregulation of inducible nitric oxide synthase (iNOS) [28]. Moreover, Trujillo-Murillo et al. [29] found that acetylsalicylic acid decreases HCV replication via the inhibition of COX–2 expression through the activation of p38 and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 (MEK1/2). In a more recent study, Yin and Zhang [30] investigated the effects of aspirin on the blocking of HCV entry. They discovered that aspirin degrades claudin–1, an HCV receptor, through the proteasome degradation pathway and inhibits the entry of all genotypes of HCV pseudoparticles [30]. Taken together, past studies suggest that aspirin could reduce HCV expression and prevent HCV re-infection in patients with chronic HCV infection through COX–2-dependent and COX–2-independent pathways [19].

We found that aspirin lowered the HCC incidence rate in HCV carriers over the first 10 years of aspirin treatment, including a 67% reduction in the occurrence rate in cases in which the duration of aspirin treatment was less than one year (Table 4; Figure 2). Moreover, the cumulative HCC incidence rate became even lower over time. Our hypothesis is that aspirin could relieve chronic inflammation via the
inhibition of the cyclooxygenase enzyme, thus lowering the occurrence of HCC at first [31–32]. However, the inhibition of the cyclooxygenase enzyme also restrains the immune system, such that an HCV infection may become uncontrolled [33–34]. Due to the resulting accumulation of liver cell damage and the duplication of HCV, the HCC incidence rate then gradually becomes higher. Nonetheless, regular close follow-up visits and aspirin treatment might help lower the incidence rate of HCC in HCV carriers, especially over the first 10 years of aspirin treatment. That said, further clinical trials are warranted to clarify the preventive effects of aspirin against HCC risk in HCV carriers.

The present study, which was based on data from National Health Insurance program in Taiwan, had the following advantages: First, the large national sample population can be taken as representative of the entire population of Taiwan from 2000 to 2013; nearly all patients in Taiwan could get the proper medical care; and only a few people would take over-the-counter drugs themselves. Hence, we could retrieve the details of patients’ information and medical records from the NHIRD. Second, cancers are categorized as serious diseases in Taiwan, such that cancer patients can apply for a “catastrophic illness card” as part of the NHI program. Most such patients’ medical visits are free when they visit outpatient departments or are admitted to a hospital, and almost all cancer patients will receive medical treatment. The present study, therefore, could identify HCV carriers and HCC patients accurately. Third, we could rather precisely collect information for 16,466 HCC patients to perform a 1:1 propensity score matching by age, sex, comorbidities, drugs, treatment course of aspirin, and index year. Due to the gross sample size and detailed/accurate matching, we could then precisely analyze the association of aspirin use with HCC risk in the HCV carriers.

There were some limitations to this study. First, the study was a retrospective study. As such, we could not trace the HCV titer in these patients and thus could not prove our hypothesis that the HCV titer might flare up because of the restrained immune response owing to aspirin. Second, there were no data regarding the aspirin doses per day of the patients, because definite data in that regard were not included in the database. However, the prescribed dose in Taiwan is usually 100 mg per day. Third, alcohol consumption also leads to a higher incidence of HCC among HCV-infected individuals. However, the effects of alcohol consumption could not be measured in this retrospective study.

**Conclusion**

In conclusion, the use of aspirin appeared to reduce the risk of HCC in HCV carriers, with the hazard ratio of 0.56, (95% CI = 0.43–0.72, \( p < 0.001 \)). Moreover, both genders exhibited significant reductions in the occurrence of HCC after aspirin use. Further clinical trials are warranted to clarify the preventive effects of aspirin against HCC risk in HCV carriers.

**Abbreviations**

aHR: Adjusted hazard ratio
CIs: Confidence intervals
COX–2: Cyclooxygenase–2
HBV: Hepatitis B virus
HCC: Hepatocellular carcinoma
HCV: Hepatitis C virus
NHI: National Health Insurance
NHIRD: National Health Insurance Research Database
NSAIDs: Non-steroidal anti-inflammatory drugs

**Declarations**

**Ethics approval and consent to participate:**

This study was approved by the Institutional Review Board (IRB) of the China Medical University and Hospital (CMUH) Research Ethics Committee (REC) (IRB permit number: CMUH–104-REC2–115). Consent to participate was waived because this study was a retrospective database analysis.

**Consent for publication:**

Not applicable.

**Availability of data and material:**

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

**Competing interests:**

The authors declare that they have no competing interests.

**Funding:**

The authors received no specific funding for this work.
Authors’ contributions:

YL, RH, TW, CW, and WH set up the research project and finished the article.

DL provided the research idea and checked the research outcomes.

SH, CH, and YS provided and analyzed the data from the National Health Insurance program.

Acknowledgements:

This work was supported by grants from the Ministry of Health and Welfare, Taiwan (MOHW107-TDU-B–212–123004), China Medical University Hospital; the Academia Sinica Stroke Biosignature Project (BM10701010021); the MOST Clinical Trial Consortium for Stroke (MOST 106–2321-B–039–005); the Tseng-Lien Lin Foundation, Taichung, Taiwan; and the Katsuzo and Kiyo Aoshima Memorial Funds, Japan.

References

1. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992;327:1899–1905.

2. Su SY, Chiang CJ, Yang YW, Lee WC. Secular trends in liver cancer incidence from 1997 to 2014 in Taiwan and projection to 2035: An age-period-cohort analysis. J Formos Med Assoc. 2019;118:444–449.

3. Chen CJ, Liang KY, Chang AS, et al. Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatology. 1991;13:398–406.

4. Yeh MM, Daniel HD, Torbenson M. Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers. Mod Pathol. 2004;17:276–83.

5. Degos F, Christidis C, Ganne-Carrie N, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut. 2000;47:131–136.

6. Cheng AS, Chan HL, Leung WK, et al. Expression of HBx and COX–2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX–2. Mod Pathol. 2004;17:1169–79.

7. Ansara AJ, Nisly SA, Arif SA, Koehler JM, Nordmeyer ST. Aspirin dosing for the prevention and treatment of ischemic stroke: an indication-specific review of the literature. Ann Pharmacother. 2010;44:851–62.

8. Johnson ES, Lanes SF, Wentworth CE, 3rd, Satterfield MH, Abebe BL, Dicker LW. A metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med. 1999;159:1248–53.
9. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed). 1988;296:313–6.

10. Pignone M, Williams CD. Aspirin for primary prevention of cardiovascular disease in diabetes mellitus. Nat Rev Endocrinol. 2010;6:619–28.

11. Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer. 2003;88:684–8.

12. Huang WK, Chiou MJ, Yu KH, et al. The association between low-dose aspirin use and the incidence of colorectal cancer: a nationwide cohort study. Aliment Pharmacol Ther. 2013;38:432–9.

13. Lin CC, Lai MS, Shau WY. Can aspirin reduce the risk of colorectal cancer in people with diabetes? A population-based cohort study. Diabet Med. 2015;32:324–31.

14. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369:1603–13.

15. Jiang HY, Huang TB, Xu L, et al. Aspirin use and lung cancer risk: a possible relationship? Evidence from an updated meta-analysis. PLoS One. 2015;10:e0122962.

16. Lapi F, Levi M, Simonetti M, et al. Risk of prostate cancer in low-dose aspirin users: A retrospective cohort study. Int J Cancer. 2016;139:205–11.

17. Jayaparakash V, Rigual NR, Moysich KB, et al. Chemoprevention of head and neck cancer with aspirin: a case-control study. Arch Otolaryngol Head Neck Surg. 2006;132:1231–6.

18. Pang Q, Jin H, Qu K, et al. The effects of nonsteroidal anti-inflammatory drugs in the incident and recurrent risk of hepatocellular carcinoma: a meta-analysis. OncoTargets Ther. 2017;10:4645–4656.

19. Ma J, Cai Z, Wei H, Liu X, Zhao Q, Zhang T. The anti-tumor effect of aspirin: What we know and what we expect. Biomed Pharmacother. 2017;95:656–661.

20. Hwang IC, Chang J, Kim K, Park SM. Aspirin use and risk of hepatocellular carcinoma in a national cohort study of Korean adults. Sci Rep. 2018;8:4968.

21. Aiolfi R, Sitia G. Emerging role of dual antiplatelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. J Hepatocell Carcinoma. 2014;1:183–6.

22. Chen DS, Kuo GC, Sung JL, et al. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infec Dis. 1990;162:817–22.

23. Pol S, Lagaye S. The remarkable history of the hepatitis C virus. Genes Immun. 2019;20:436–446.

24. Ho CM, Lee CH, Lee MC, et al. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study. BMC Cancer. 2018;18:401.

25. Iannacone M, Sitia G, Isogawa M, et al. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med. 2005;11:1167–9.

26. Sitia G, Aiolfi R, Di Lucia P, et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci USA. 2012;109:E2165–72.
27. Rivas-Estilla AM, Bryan-Marrugo OL, Trujillo-Murilo K, et al. Cu/Zn superoxide dismutase (SOD1) induction is implicated in the antioxidative and antiviral activity of acetylsalicylic acid in HCV-expressing cells. Am J Physiol Gastrointest Liver Physiol. 2012;302:G1264–73.

28. Rios-Ibarra CP, Lozano-Sepulveda S, Munoz-Espinosa L, Rincon-Sanchez AR, Cordova-Fletes C, Rivas-Estilla AM. Downregulation of inducible nitric oxide synthase (iNOS) expression is implicated in the antiviral activity of acetylsalicylic acid in HCV-expressing cells. Arch Virol. 2014;159:3321–8.

29. Trujillo-Murilo K, Rincon-Sanchez AR, Martinez-Rodriguez H, et al. Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase pathways. Hepatology. 2008;47:1462–72.

30. Yin P, Zhang L. Aspirin inhibits hepatitis C virus entry by downregulating claudin-1. J Viral Hepat. 2016;23:62–4.

31. O'Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer. 2001;85:473–83.

32. Yu LX, Ling Y, Wang HY. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. NPJ Precis Oncol. 2018;2:6.

33. Shin EC, Sung PS, Park SH. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol. 2016;16:509–23.

34. Sun P, Williams M, Nagabhushana N, Jani V, Defang G, Morrison BJ. NK cells activated through antibody-dependent cell cytotoxicity and armed with degranulation/IFN-γ production suppress antibody-dependent enhancement of Dengue viral infection. Sci Rep. 2019;9:1109.

Tables
Table 1 Demographic characteristics and covariates in HCV patients (carriers) treated with and without aspirin.

| Variables                    | Aspirin No (N=1911) | %    | Aspirin Yes (N=1911) | %    | p value* |
|------------------------------|---------------------|------|----------------------|------|----------|
| Gender                       |                     |      |                      |      |          |
| Female                       | 1027 53.7           |      | 997 52.2             |      | 0.33     |
| Male                         | 884 46.3            |      | 914 47.8             |      |          |
| Age, years                   |                     |      |                      |      |          |
| <40                          | 98 5.13             |      | 96 5.02              |      | 0.01     |
| 40-59                        | 606 31.7            |      | 580 30.4             |      |          |
| 60-79                        | 936 49.0            |      | 1025 53.6            |      |          |
| ≥80                          | 271 14.2            |      | 210 11.0             |      |          |
| Mean(SD)                     | 64.6 14.4           |      | 64.3 13.5            |      | 0.58†    |
| Baseline comorbidity         |                     |      |                      |      |          |
| Hypertension                 | 1462 76.5           |      | 1410 73.8            |      | 0.05     |
| Diabetes mellitus            | 905 47.4            |      | 848 44.4             |      | 0.06     |
| Moderate or severe liver disease | 34 1.78  |      | 23 1.2              |      | 0.14     |
| Myocardial infarction        | 123 6.44            |      | 133 6.96            |      | 0.52     |
| Congestive heart failure     | 431 22.6            |      | 429 22.5            |      | 0.94     |
| Ischemic stroke              | 1245 65.2          |      | 1212 63.4          |      | 0.27     |
| Drugs                        |                     |      |                      |      |          |
| Anti-hypertensive agents     | 1003 52.5           |      | 1506 78.8           |      | <0.001   |
| Hypoglycemic agents          | 114 5.97            |      | 141 7.38            |      | 0.08     |
| Coumadin and heparin         | 55 2.88             |      | 175 9.16            |      | <0.001   |
| Other antithrombotic agents  | 153 8.01            |      | 491 25.7            |      | <0.001   |
| NSAIDs                       | 931 48.7            |      | 1140 59.7           |      | <0.001   |

*Chi-square test; †Two sample t-test.
Abbreviations: SD, standard deviation; NSAIDs, non-steroidal anti-inflammatory drugs.
Table 2 Cox model measured hazard ratios (HRs) and 95% confidence intervals of HCC occurrence associated with and without aspirin use and covariates among HCV carriers.

| Characteristics                  | Event no. (n=278) | Crude HR (95% CI) | p value | Adjusted HR (95% CI) | p value |
|----------------------------------|-------------------|-------------------|---------|----------------------|---------|
| **Aspirin**                      |                   |                   |         |                      |         |
| No                               | 147               | 1                 | reference | 1                   | reference |
| Yes                              | 131               | 0.73 (0.58-0.93)  | 0.01    | 0.56 (0.43-0.72)    | <0.001  |
| **Gender**                       |                   |                   |         |                      |         |
| Female                           | 123               | 1                 | reference | 1                   | reference |
| Male                             | 155               | 1.55 (1.23-1.97)  | <0.001  | 1.71 (1.35-2.18)    | <0.001  |
| **Age, years**                   |                   |                   |         |                      |         |
| <40                              | 2                 | 1                 | reference | 1                   | reference |
| 40-59                            | 58                | 5.83 (1.42-23.87) | 0.01    | 5.42 (1.32-22.25)   | 0.02    |
| 60-79                            | 192               | 15.63 (3.88-63.02)| <0.001  | 13.45 (3.31-54.59)  | <0.001  |
| ≥80                              | 26                | 14.79 (3.5-62.56) | <0.001  | 12.24 (2.87-52.18)  | <0.001  |
| **Baseline comorbidity**         |                   |                   |         |                      |         |
| Hypertension                     |                   |                   |         |                      |         |
| No                               | 70                | 1                 | reference | 1                   | reference |
| Yes                              | 208               | 1.11 (0.85-1.46)  | 0.45    | 1.33 (0.99-1.79)    | 0.06    |
| Diabetes mellitus                |                   |                   |         |                      |         |
| No                               | 169               | 1                 | reference | 1                   | reference |
| Yes                              | 109               | 0.84 (0.66-1.06)  | 0.15    | 0.81 (0.63-1.05)    | 0.11    |
| Moderate or severe liver disease |                   |                   |         |                      |         |
| No                               | 275               | 1                 | reference | 1                   | reference |
| Yes                              | 3                 | 0.77 (0.25-2.39)  | 0.65    | 0.83 (0.26-2.59)    | 0.75    |
| Myocardial infarction            |                   |                   |         |                      |         |
| No                               | 269               | 1                 | reference | 1                   | reference |
| Yes                              | 9                 | 0.53 (0.27-1.03)  | 0.06    | 0.59 (0.3-1.15)     | 0.12    |
| Congestive heart failure         |                   |                   |         |                      |         |
|          | Yes | 1  | reference |     | 1  | reference |
|----------|-----|----|-----------|-----|----|-----------|
| Ischemic stroke | 48  | 0.84 | (0.61-1.15) | 0.27 | 0.87 | (0.63-1.2) |
|          | Yes | 152 | 0.86      | (0.68-1.09) | 0.21 | 0.83      | (0.64-1.07) |

**Drugs**

| Anti-hypertensive agents |          |     |     |     |     |     |
|--------------------------|----------|----|----|----|----|----|
| No  | 75  | 1  | reference |     | 1  | reference |
| Yes | 203 | 1.92 | (1.47-2.5) | <0.001 | 1.94 | (1.45-2.6) | <0.001 |

| Hypoglycemic agents |          |     |     |     |     |     |
|---------------------|----------|----|----|----|----|----|
| No  | 265 | 1  | reference |     | 1  | reference |
| Yes | 13  | 0.88 | (0.51-1.54) | 0.67 | 0.85 | (0.48-1.48) |

| Coumadin and heparin |          |     |     |     |     |     |
|----------------------|----------|----|----|----|----|----|
| No  | 271 | 1  | reference |     | 1  | reference |
| Yes | 7   | 0.61 | (0.29-1.28) | 0.19 | 0.52 | (0.24-1.11) |

| Other antithrombotic agents |          |     |     |     |     |     |
|-----------------------------|----------|----|----|----|----|----|
| No  | 232 | 1  | reference |     | 1  | reference |
| Yes | 46  | 1.18 | (0.86-1.62) | 0.30 | 1.06 | (0.76-1.48) |

| NSAIDs |          |     |     |     |     |     |
|--------|----------|----|----|----|----|----|
| No     | 134 | 1  | reference |     | 1  | reference |
| Yes    | 144 | 0.83 | (0.66-1.05) | 0.13 | 0.83 | (0.65-1.05) |

Abbreviations: HR, hazard ratio; CI, confidence interval; NSAIDs, non-steroidal anti-inflammatory drugs.

Adjusted HR: adjusted for gender, age, hypertension, diabetes mellitus, moderate or severe liver disease, myocardial infarction, congestive heart failure, ischemic stroke, anti-hypertension agents, hypoglycemic agents, coumadin and heparin, other antithrombotic agents and NSAIDs in Cox proportional hazards regression.
Table 3. Incidence rates, hazard ratios, and confidence intervals of HCC among different stratifications of HCV patients with and without aspirin use.

| Variables                  | Aspirin          | Aspirin VS. Non-aspirin |
|----------------------------|------------------|-------------------------|
|                            | No (n=1911)      | Yes (n=1911)            |
|                            | Event | Person years | IR†  | Event | Person years | IR†  | Crude HR (95% CI) | Adjusted HR (95% CI) |
| Overall                    | 147   | 6848         | 2.15 | 131   | 8546         | 1.53 | 0.73(0.58-0.93)** | 0.56(0.43-0.72)*** |
| Gender                     |       |              |      |       |              |      |                  |                     |
| Female                     | 66    | 3838         | 1.72 | 57    | 4707         | 1.21 | 0.72(0.51-1.03)  | 0.51(0.35-0.76)*** |
| Male                       | 81    | 3010         | 2.69 | 74    | 3839         | 1.93 | 0.72(0.53-0.99)*  | 0.59(0.42-0.83)** |
| Age, years                 |       |              |      |       |              |      |                  |                     |
| <40                        | 0     | 592          | 0    | 2     | 633          | 0.32 |                  |                     |
| 40-59                      | 31    | 2929         | 1.06 | 27    | 3069         | 0.88 | 0.83(0.5-1.39)   | 0.64(0.35-1.14)     |
| 60-79                      | 98    | 2888         | 3.39 | 94    | 4325         | 2.17 | 0.65(0.49-0.87)** | 0.56(0.41-0.76)*** |
| ≥80                        | 18    | 440          | 4.09 | 8     | 518          | 1.54 | 0.44(0.19-1.01)  | 0.45(0.18-1.11)     |
| Baseline comorbidity       |       |              |      |       |              |      |                  |                     |
| Hypertension               |       |              |      |       |              |      |                  |                     |
| No                         | 39    | 1713         | 2.28 | 31    | 2557         | 1.21 | 0.55(0.34-0.88)*  | 0.39(0.23-0.65)*** |
| Yes                        | 108   | 5135         | 2.1  | 100   | 5989         | 1.67 | 0.81(0.62-1.06)  | 0.63(0.47-0.85)** |
| Diabetes mellitus          |       |              |      |       |              |      |                  |                     |
| No                         | 90    | 3692         | 2.44 | 79    | 5060         | 1.56 | 0.65(0.48-0.88)** | 0.49(0.35-0.68)*** |
| Yes                        | 57    | 3156         | 1.81 | 52    | 3486         | 1.49 | 0.85(0.58-1.24)  | 0.68(0.45-1.03)     |
| Moderate or severe liver   |       |              |      |       |              |      |                  |                     |
| disease                    |       |              |      |       |              |      |                  |                     |
| No                         | 145   | 6711         | 2.16 | 130   | 8468         | 1.54 | 0.73(0.57-0.92)** | 0.56(0.43-0.73)*** |
| Yes                        | 2     | 137          | 1.46 | 1     | 78           | 1.28 | 0.8(0.07-8.85)    |                   |
| Myocardial infarction      |       |              |      |       |              |      |                  |                     |
| No                         | 143   | 6443         | 2.22 | 126   | 8057         | 1.56 | 0.72(0.57-0.92)** | 0.55(0.42-0.72)*** |
| Yes                        | 4     | 405          | 0.99 | 5     | 489          | 1.02 | 1.02(0.27-3.82)  | 0.72(0.16-3.23)     |
|                     | No     | Yes    | IR   | HR   | 95%CI       | Adjusted HR | 95%CI       |
|---------------------|--------|--------|------|------|-------------|-------------|-------------|
| Congestive heart failure | No     | 127    | 5443 | 2.33 | 1.48        | 0.65(0.5-0.84)** | 0.52(0.39-0.69)*** |
|                     | Yes    | 20     | 1406 | 1.42 | 1.78        | 1.25(0.7-2.23) | 0.79(0.42-1.5)    |
| Ischemic stroke     | No     | 66     | 2754 | 2.4  | 1.56        | 0.66(0.46-0.93)* | 0.48(0.33-0.71)*** |
|                     | Yes    | 81     | 4094 | 1.98 | 1.51        | 0.79(0.58-1.09) | 0.62(0.43-0.88)**  |
| Drugs               | Anti-hypertensive agents | No     | 56    | 4333 | 1.29        | 0.87        | 0.69(0.41-1.16) | 0.58(0.33-1.01) |
|                     |        | Yes    | 91    | 2515 | 3.62        | 1.76        | 0.51(0.38-0.67)*** | 0.53(0.4-0.71)*** |
|                     | Hypoglycemic agents     | No     | 141   | 6548 | 2.15        | 1.54        | 0.73(0.57-0.93)* | 0.55(0.42-0.72)*** |
|                     |        | Yes    | 6     | 300  | 2           | 1.43        | 0.65(0.21-2.03) | 0.71(0.2-2.52)    |
|                     | Coumadin and heparin    | No     | 145   | 6765 | 2.14        | 1.57        | 0.75(0.59-0.95)* | 0.56(0.43-0.73)*** |
|                     |        | Yes    | 2     | 83   | 2.4         | 0.98        | 0.4(0.07-2.19)   | 0.41(0.05-3.18)   |
|                     | Other antithrombotic agents | No     | 136   | 6531 | 2.08        | 1.43        | 0.71(0.54-0.92)** | 0.53(0.4-0.7)***  |
|                     |        | Yes    | 11    | 318  | 3.46        | 1.9         | 0.56(0.29-1.12)  | 0.68(0.34-1.37)   |
|                     | NSAIDs  | No     | 69    | 3535 | 1.95        | 2.09        | 1.07(0.76-1.5)   | 0.79(0.54-1.14)   |
|                     |        | Yes    | 78    | 3313 | 2.35        | 1.21        | 0.54(0.39-0.74)*** | 0.41(0.29-0.59)*** |

Abbreviations: IR, incidence rates, per 100 person-years; HR, hazard ratio; CI, confidence interval; NSAIDs, non-steroidal anti-inflammatory drugs.

Adjusted HR: adjusted for gender, age, hypertension, diabetes mellitus, moderate or severe liver disease, myocardial infarction, congestive heart failure, ischemic stroke, anti-hypertension agents, hypoglycemic agents, coumadin and heparin, other antithrombotic agents and NSAIDs in Cox proportional hazards regression.
Table 4 The dose responses to aspirin among the HCV patients.

| Duration of aspirin use | Event no. | Crude          | Adjusted        |
|-------------------------|-----------|----------------|-----------------|
|                         | (n=278)   | HR  | (95% CI) | p value | HR  | (95% CI) | p value |
| Non-user                | 147       | 1   | reference | 1       | reference |
| <1 year                 | 93        | 0.74 | (0.57-0.96) | 0.02 | 0.63 | (0.48-0.83) | <0.001 |
| 1-2 years               | 12        | 0.52 | (0.29-0.93) | 0.03 | 0.33 | (0.18-0.61) | <0.001 |
| 2-3 years               | 11        | 0.94 | (0.51-1.73) | 0.84 | 0.6  | (0.32-1.13) | 0.11   |
| ≥3 years                | 15        | 0.8  | (0.47-1.37) | 0.42 | 0.45 | (0.26-0.79) | 0.005  |

Abbreviations: HR, hazard ratio; CI, confidence interval; NSAIDs, non-steroidal anti-inflammatory drugs.

Adjusted HR: adjusted for gender, age, hypertension, diabetes mellitus, moderate or severe liver disease, myocardial infarction, congestive heart failure, ischemic stroke, anti-hypertension agents, hypoglycemic agents, coumadin and heparin, other antithrombotic agents and NSAIDs in Cox proportional hazards regression.

**Figures**
1 million individuals in LHID2000

16,466 HCV patients

Aspirin users from 2000 to 2012 n=2,980

Exclusion Criteria
1. Patient took Interferon or direct-acting anti-viral (n=144)
2. Diagnosis date of liver cancer before the index date (n=144)
3. Age less than 20 years (n=0)
4. HBV carrier (n=688)

Aspirin users n=2,004

Non-aspirin users from 2000 to 2012 n=7,771

Exclusion Criteria
1. Patient took Interferon or direct-acting anti-viral (n=591)
2. Diagnosis date of liver cancer before the index date (n=691)
3. Age less than 20 years (n=33)
4. HBV carrier (n=1,850)

Non-aspirin users n=4,606

Using 1:1 propensity score match by sex, age, HCV diagnosis year, and number of years of aspirin use

1,911:1,911 Aspirin users and non-aspirin users

Figure 1

Flow diagram of the selection of study subjects.
Figure 2

Kaplan-Meier curves showing the cumulative incidence of hepatocellular carcinoma (HCC) in hepatitis C virus carriers with or without aspirin treatment. Red line presents aspirin users. Black line presents non-aspirin users. X-axis presents follow-up years. Y-axis presents cumulative incidence of hepatocellular carcinoma.

Patients at Risk

|                  | Aspirin User | Non-Aspirin User |
|------------------|--------------|------------------|
| Follow-up Years  |              |                  |
|                  | 0            | 2                |
|                  | 1267         | 1144             |
|                  | 904          | 711              |
|                  | 595          | 406              |
|                  | 357          | 206              |
|                  | 161          | 95               |
|                  | 37           | 31               |

Log Rank p value = 0.0090